Global Parkinson’s Disease Market 2016 Edition: Market Trends, Growth Drivers, Competitive Landscape & 2017 Forecasts Discussed in New Research Report

Press Release

Parkinson’s Disease (PD) is a chronic and progressive neurodegenerative or movement disorder which involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinson’s primarily affects neurons in an area of the brain called the “substantia nigra”. The early signs and symptoms may be mild and may go unnoticed initially. The cause of this disease is mainly unknown with no cure till date but there exist several treatment options such as medications and surgery.

The Global Parkinson’s Disease Market Report: 2016 Edition research of 51 pages with 32 Charts and 10 Tables, 4 company profiles to the pharmaceuticals industry segment of its online data and intelligence library, now available at

The current treatment market for Parkinson’s disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinson’s disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinson’s along with possibility of developing “Stem Cell” as a treatment therapy.

Company Coverage of Parkinson’s Disease Market:
• Biotie Therapies Corp.
• Adamas Pharmaceuticals Inc.
• Lundbeck
• Novartis

The Parkinson’s disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinson’s disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.

Purchase a copy of this Parkinson’s Disease Market research report at USD 800 (Single User License)

The report, “Global Parkinson’s disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Major Points from Table of Contents ( Provided in Parkinson’s Disease Market:

Table of Contents

1. Market Overview
1.1 Introduction
1.2 Fundamental Features
1.3 Types of Parkinson’s Disease
1.4 Risk Factors
1.5 Treatment Options

2. Global Market
2.1 Global Parkinson’s Disease Drug Market by Value
2.1.1 Global Parkinson’s Disease Drug Market by Region
2.1.2 Global Parkinson’s Disease Market by Drug Class
2.1.3 Global Parkinson’s Disease Patient Population by Severity
2.1.4 Global Parkinson’s Disease Patient Population by Region

3. Regional Markets
3.1 The U.S.
3.1.1 The U.S. Parkinson’s Disease Market by Value & Volume
3.1.2 The U.S. Parkinson’s Disease Market Value by Category
3.1.3 The U.S. Parkinson’s Disease Market Volume by Category
3.1.4 The U.S. Parkinson’s Disease Market by Drug Class
3.1.5 The U.S. Parkinson’s Disease Branded Drugs Market
3.1.6 The U.S. Parkinson’s Disease Generic Drugs Market
3.2 The European Union
3.2.1 The E.U. Parkinson’s Patient Prevalence & Diagnosis
3.2.2 The European Parkinson’s Disease Drug Market by Value
3.3 Japan
3.3.1 Japan’s Parkinson’s Disease Drug Market by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Level of Toxin Exposure
4.1.2 Rising Life Expectancy
4.1.3 Rising Male Population
4.1.4 Increasing Ageing Population
4.1.5 Global Healthcare Expenditure
4.1.6 Pesticides Consumption
4.2 Trends
4.2.1 Late-Stage Drug Development for Parkinson’s Disease
4.2.2 Stem-Cell Therapy as Potential Treatment
4.2.3 Biologics under Development for Parkinson’s Disease
4.3 Challenges
4.3.1 Generic Erosion
4.3.2 Parkinson’s Treatment associated with Higher Risk of Melanoma
4.3.3 Current Treatment Limitation

5. Competitive Landscape
5.1 The U.S. Parkinson’s Disease Branded Drug Market by Company
5.2 The U.S. Parkinson’s Disease Generic Drug Market by Company

Explore more related reports on pharmaceuticals market at